Filing Flows › Syndax Pharmaceuticals (SNDX) › Guidance & outlook
Syndax Pharmaceuticals (SNDX) guidance and outlook
Syndax Pharmaceuticals' 10-Q filed Nov 2, 2026 makes 28 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 2, 2026
- We plan to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional therapeutics to expand our pipeline.
- SNDX-62122 is the first molecule from our library of internally developed and wholly owned next-generation menin inhibitors that we intend to advance into new areas.
- We expect the development of SNDX-62122 to be informed and de-risked by a planned Phase 1/2 proof-of-principle trial of revumenib in MF.
- We expect to have a major presence at upcoming medical meetings, with the presentation in the fourth quarter of 2026 of new/updated revumenib data including:
- We expect to publish safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026.
- These data provide the basis for our plans to develop SNDX-62122, an internally developed, next-generation menin inhibitor, for MF.
- We expect the RAVEN trial to initiate in the fourth quarter of 2026.
- We expect the MenTain Phase 2 trial to initiate in the first quarter of 2027.
- The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027.
- The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028.
- We expect to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027.
- SNDX-62122 is the first candidate from a library of internally developed, wholly owned next-generation menin inhibitors that we intend to advance into new areas.
Syndax Pharmaceuticals' latest quarter
Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%, net loss $49.4M, operating cash flow −$27.3M. The chart follows the revenue to costs, profit and cash.
Questions
What does Syndax Pharmaceuticals expect?
We plan to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional therapeutics to expand our pipeline. SNDX-62122 is the first molecule from our library of internally developed and wholly owned next-generation menin inhibitors that we intend to advance into new areas. We expect the development of SNDX-62122 to be informed and de-risked by a planned Phase 1/2 proof-of-principle trial of revumenib in MF.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.